Crispr Therapeutics AG Capital Reinvestment Ratio
Crispr Therapeutics AG capital reinvestment ratio. Crispr Therapeutics AG (CRSP) has a Capital Reinvestment Ratio of 0.01x as of March 2024, meaning it reinvests 0% of its operating cash flow ($109.75 Million) in capital expenditures ($721.00K). Check how aggressively does Crispr Therapeutics AG reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Crispr Therapeutics AG (2015–2021)
Capital reinvestment ratio of Crispr Therapeutics AG from 2015 to 2021. This chart tracks Crispr Therapeutics AG's Capital Reinvestment Ratio across 3 annual periods. Also explore Crispr Therapeutics AG equity growth rate to track the company's year-over-year net asset growth rate.
Crispr Therapeutics AG Capital Reinvestment Ratio by Year (2015–2021)
Crispr Therapeutics AG capital reinvestment ratio by year from 2015 to 2021. For the full cash flow conversion analysis, see how efficiently does Crispr Therapeutics AG generate cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.15x | $538.97 Million | $81.70 Million | ▲ +28.5% |
| 2019 | 0.12x | $56.68 Million | $6.68 Million | ▲ +507.3% |
| 2015 | 0.02x | $59.43 Million | $1.15 Million | — |